Strides Pharma (STR) has decided to sell its entire stake in Arrow (Australian business) to Apotex for a consideration of AUD394m (US282m). The stake sale -which implies an attractive valuation of 19x EV/EBITDA - would enable STR to reduce its debt by at least USD160m.